RT Journal Article
SR Electronic
T1 Analysis of the time evolution of SARS-CoV-2 lethality rate in Italy: Evidence of an unaltered virus potency
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.06.12.20129387
DO 10.1101/2020.06.12.20129387
A1 Balasco, Nicole
A1 d’Alessandro, Vincenzo
A1 Smaldone, Giovanni
A1 Vitagliano, Luigi
YR 2020
UL http://medrxiv.org/content/early/2020/06/14/2020.06.12.20129387.abstract
AB In recent months, the entire world is facing a dramatic health emergency caused by the diffusion of a hitherto unknown coronavirus (SARS-CoV-2). Despite the efforts, the understanding of the many facets of the pandemic is still rather limited. In the present manuscript, we have monitored the evolution of the lethality rate in Italy by using the data collected over the last three months. Our data indicate that there is a striking correlation between the number of infected people of a certain week and the deaths of the following one. Despite the overall simplicity of the applied approach and its many approximations, the analysis of the Italian scenario provides some interesting insights into the pandemic. Indeed, we have found that the lethality rate is virtually unchanged over the last two months. This implies that the reduction of the deaths is strictly connected to the decrease of cases. Unfortunately, the present study does not support the idea that the virus potency has lowered in the last weeks, as our data demonstrate that the likelihood of a fatal outcome after the infection has not decreased in the recent outbreak evolution. Moreover, we show that the lethality rate is still very high in the country (≈13.5%). Since this number is remarkably higher if compared to the actual lethality estimates made worldwide, this finding suggests that the number of detected cases may be a gross underestimation of the actual infected people, likely due to the presence of a significant number of non-symptomatic or paucisymptomatic individuals in the population.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThe present activities have been performed in the framework of project 'RicErCa e sviluppO VERsus COVID19 in Campania RECOVER-COVID19' funded by the Campania RegionAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This works is exempted from IRB/oversightAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData used for the analyses are reported in the supplementary material and are available from the authors